Showing results (391-400 of 478) with videos related to
Sort By:
Pageof 48
The American Journal of Cardiology|November 15, 2011
Comparison of incidence of bleeding and mortality of men versus women with ST-elevation myocardial infarction treated with fibrinolysisRajendra H Mehta, Amanda S Stebbins, Renato D Lopes, et al.Journal of the American College of Cardiology|February 21, 2004
Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trialHitinder S Gurm, A Michael Lincoff, David Lee, et al.American Heart Journal|February 9, 2002
Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network TrialKenneth W Mahaffey, Matthew T Roe, Christopher K Dyke, et al.American Heart Journal|August 1, 2006
The prognostic value of the admission and predischarge electrocardiogram in acute coronary syndromes: the GUSTO-IIb ECG Core Laboratory experienceShaun G Goodman, Yuling Fu, Anatoly Langer, et al.European Heart Journal|December 4, 2003
International variation in the use of evidence-based medicines for acute coronary syndromesJudith M Kramer, L Kristin Newby, Wei Ching Chang, et al.Contemporary Clinical Trials Communications|January 19, 2019
Digital recruitment and enrollment in a remote nationwide trial of screening for undiagnosed atrial fibrillation: Lessons from the randomized, controlled mSToPS trialKatie Baca-Motes, Alison M Edwards, Jill Waalen, et al.Nature Biomedical Engineering|March 27, 2019
Mechanical activation of noncoding-RNA-mediated regulation of disease-associated phenotypes in human cardiomyocytesAditya Kumar, Stephanie K Thomas, Kirsten C Wong, et al.The American Journal of Cardiology|May 12, 2009
Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial)Arijit Dasgupta, Steven R Steinhubl, Deepak L Bhatt, et al.The American Journal of Cardiology|July 31, 2003
Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials)Thaddeus R Tolleson, L Kristin Newby, Robert A Harrington, et al.European Heart Journal|August 4, 2007
An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trialThomas H Wang, Deepak L Bhatt, Keith A A Fox, et al.Pageof 48